Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Sutro Biopharma, Inc. operates as a clinical-stage oncology company.
It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+.
The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors.
It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.95 Decreased by -11.76% | -0.92 Decreased by -3.26% |
| Mar 25, 24 | 0.52 Increased by +176.47% | -0.82 Increased by +163.41% |
| Nov 13, 23 | -0.81 Decreased by -118.92% | -0.74 Decreased by -9.46% |
| Aug 10, 23 | -0.64 Decreased by -16.36% | -0.73 Increased by +12.33% |
| May 15, 23 | -0.85 Decreased by -1.19% | -0.81 Decreased by -4.94% |
| Mar 30, 23 | -0.68 Increased by +18.07% | -0.62 Decreased by -9.68% |
| Nov 8, 22 | -0.37 Increased by +44.78% | -0.74 Increased by +50.00% |
| Aug 8, 22 | -0.55 Decreased by -323.08% | -0.46 Decreased by -19.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 16.92 M Decreased by -32.70% | -49.28 M Decreased by -177.41% | Decreased by -291.21% Decreased by -312.19% |
| Jun 30, 23 | 10.41 M Decreased by -62.94% | -38.52 M Decreased by -48.10% | Decreased by -370.00% Decreased by -299.64% |
| Mar 31, 23 | 12.67 M Increased by +114.92% | -50.05 M Decreased by -28.04% | Decreased by -394.90% Increased by +40.42% |
| Dec 31, 22 | 8.63 M Decreased by -18.98% | -37.09 M Increased by +2.70% | Decreased by -429.73% Decreased by -20.09% |
| Sep 30, 22 | 25.15 M Increased by +195.26% | -17.77 M Increased by +42.51% | Decreased by -70.65% Increased by +80.53% |
| Jun 30, 22 | 28.10 M Increased by +0.17% | -26.01 M Decreased by -322.82% | Decreased by -92.58% Decreased by -322.11% |
| Mar 31, 22 | 5.90 M Decreased by -59.77% | -39.09 M Decreased by -28.75% | Decreased by -662.85% Decreased by -220.08% |
| Dec 31, 21 | 10.65 M Increased by +28.70% | -38.13 M Increased by +35.97% | Decreased by -357.85% Increased by +50.25% |